Top Markets
Coin of the day
Generate Biomedicines, Inc. Generate Biomedicines, Inc.

Generate Biomedicines, Inc.

GENB
株式のランク #6385
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative... Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
株価
$15.88
時価総額
$2.04B
変化(1日)
-1.61%
変化(1年)
-
US
取引 Generate Biomedicines, Inc. (GENB)

カテゴリー

Generate Biomedicines, Inc.(GENB)のEPS
2026 時点のEPS TTM: 0
Generate Biomedicines, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Generate Biomedicines, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH